RU2003138080A - Фармацевтическая композиция с антигиперлипидемической активностью - Google Patents

Фармацевтическая композиция с антигиперлипидемической активностью Download PDF

Info

Publication number
RU2003138080A
RU2003138080A RU2003138080/15A RU2003138080A RU2003138080A RU 2003138080 A RU2003138080 A RU 2003138080A RU 2003138080/15 A RU2003138080/15 A RU 2003138080/15A RU 2003138080 A RU2003138080 A RU 2003138080A RU 2003138080 A RU2003138080 A RU 2003138080A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
antihyperlipidemic activity
obesity
antihyperlipidemic
activity
Prior art date
Application number
RU2003138080/15A
Other languages
English (en)
Other versions
RU2292891C2 (ru
Inventor
Клаус МЮНТЕР (DE)
Клаус МЮНТЕР
Михаэль КИРХЕНГАСТ (DE)
Михаэль КИРХЕНГАСТ
Original Assignee
ЭББОТТ ГмбХ унд Ко. КГ (DE)
Эбботт Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭББОТТ ГмбХ унд Ко. КГ (DE), Эбботт Гмбх Унд Ко. Кг filed Critical ЭББОТТ ГмбХ унд Ко. КГ (DE)
Publication of RU2003138080A publication Critical patent/RU2003138080A/ru
Application granted granted Critical
Publication of RU2292891C2 publication Critical patent/RU2292891C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (1)

  1. Фармацевтическая композиция с антигиперлипидемической активностью, содержащая активное вещество, отличающаяся тем, что в качестве активного вещества содержит соединение общей формулы (I)
    Figure 00000001
    где R означает метокси и R1 означает метил или метокси
    или
    R означает метил или группу
    Figure 00000002
    и R1 означает метил.
RU2003138080/15A 1997-12-05 2003-12-29 Фармацевтическая композиция с антигиперлипидемической активностью RU2292891C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19754082.1 1997-12-05
DE19754082A DE19754082A1 (de) 1997-12-05 1997-12-05 Methode zur Bekämpfung der Fettleibigkeit

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2000117857/14A Division RU2000117857A (ru) 1997-12-05 1998-11-21 Способ борьбы с ожирением

Publications (2)

Publication Number Publication Date
RU2003138080A true RU2003138080A (ru) 2005-06-10
RU2292891C2 RU2292891C2 (ru) 2007-02-10

Family

ID=7850913

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003138080/15A RU2292891C2 (ru) 1997-12-05 2003-12-29 Фармацевтическая композиция с антигиперлипидемической активностью

Country Status (16)

Country Link
US (1) US6197780B1 (ru)
EP (1) EP1035851B1 (ru)
JP (1) JP2002512173A (ru)
KR (1) KR20010032779A (ru)
CN (1) CN1152685C (ru)
AT (1) ATE204172T1 (ru)
AU (1) AU751053B2 (ru)
BR (1) BR9815335A (ru)
CA (1) CA2311423C (ru)
CZ (1) CZ300442B6 (ru)
DE (2) DE19754082A1 (ru)
ES (1) ES2162493T3 (ru)
HU (1) HUP0100171A3 (ru)
NO (2) NO324694B1 (ru)
RU (1) RU2292891C2 (ru)
WO (1) WO1999029308A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
EP1130027A1 (de) * 2000-02-29 2001-09-05 Aventis Pharma Deutschland GmbH Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben
US20050175667A1 (en) * 2004-02-10 2005-08-11 Wenda Carlyle Use of endothelin antagonists to prevent restenosis
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
LT2776038T (lt) 2011-11-11 2018-04-25 Gilead Apollo, Llc Acc inhibitoriai ir jų panaudojimas
EA201700155A1 (ru) * 2014-10-20 2017-10-31 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Фармацевтическая композиция для лечения туберкулеза
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
CA3004796C (en) 2015-11-25 2023-11-14 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
EP3380479B1 (en) 2015-11-25 2022-12-07 Gilead Apollo, LLC Triazole acc inhibitors and uses thereof
HUE053175T2 (hu) 2015-11-25 2021-06-28 Gilead Apollo Llc ACC-gátló észterek és azok alkalmazása
BR112018009212B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Método para controlar patógenos fúngicos agrícolas
CN119977993A (zh) 2016-03-02 2025-05-13 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012499A1 (fr) 1992-12-01 1994-06-09 The Green Cross Corporation Derive de 1,8-naphthyridin-2-one et utilisation de ce derive
US5998468A (en) * 1995-08-24 1999-12-07 Warner-Lambert Company Furanone endothelin antagonists
JP3116347B2 (ja) * 1996-11-13 2000-12-11 田辺製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
NO324694B1 (no) 2007-12-03
CZ20002006A3 (cs) 2000-11-15
CA2311423A1 (en) 1999-06-17
DE19754082A1 (de) 1999-06-10
BR9815335A (pt) 2000-10-17
AU2153599A (en) 1999-06-28
NO20074419L (no) 2000-06-02
EP1035851B1 (de) 2001-08-16
ES2162493T3 (es) 2001-12-16
CN1152685C (zh) 2004-06-09
JP2002512173A (ja) 2002-04-23
HK1037141A1 (en) 2002-02-01
AU751053B2 (en) 2002-08-08
CA2311423C (en) 2008-01-29
US6197780B1 (en) 2001-03-06
HUP0100171A3 (en) 2003-10-28
CN1301162A (zh) 2001-06-27
CZ300442B6 (cs) 2009-05-20
WO1999029308A3 (de) 1999-09-30
WO1999029308A2 (de) 1999-06-17
EP1035851A2 (de) 2000-09-20
RU2292891C2 (ru) 2007-02-10
NO20002777D0 (no) 2000-05-30
NO20002777L (no) 2000-06-02
KR20010032779A (ko) 2001-04-25
DE59801230D1 (de) 2001-09-20
HUP0100171A2 (hu) 2003-02-28
ATE204172T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
RU2214418C2 (ru) Аналоги glp-1
RU2003138080A (ru) Фармацевтическая композиция с антигиперлипидемической активностью
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
DE60031441D1 (de) Immobilisierung von proteinen mit hilfe eines polypeptidsegments
DE3881668D1 (de) Piezoelektrische vibrator-pumpe.
EA199800733A1 (ru) Антагонисты рецептора il-8
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
EA200000311A1 (ru) Новый белок иммунной системы - кау
IT8847693A0 (it) Fenil carbammato farmacologicamente attivo, suo procedimento di preparazione e composizione farmaceutica che lo contiene
RU94045826A (ru) Моноклональные антитела против рецептора интерферона, с нейтрализующим действием против интерферона типа i
DE3676670D1 (de) Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
BR9609653A (pt) Compostos e composições farmacêuticas contendo os mesmos
NO872658D0 (no) Vibratorplate.
IT1231012B (it) Composizione farmaceutica per uso orale contenente nac.
DE69728914D1 (de) Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen
BG96323A (bg) Нов полипептид и анти-нiv лекарство,получено от него
TR199901761T2 (xx) IL-8 resept�r antagonistleri.
BR9800913A (pt) Promotor de gene cdc25b, preparação e uso do mesmo.
ITTO960496A0 (it) Modificatione di farmaci polipeptidici per accrescere il flusso per e-lettrotrasporto.
DE60014343D1 (de) N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
EA200000092A1 (ru) Противоаллергические средства
DE69302851D1 (de) Von der Stapelunterseite, durch Reibung abfordernde, Blattzufuhrvorrichtung
BR9808625A (pt) O uso de proteìnas extraìveis de órgãos de animal para a preparação de medicamentos para o tratamento de condições patológicas caracterizadas por hiperprodução de fator de necrose de tumor (tnf)
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20141122